REVIEW PAPER
Prevalence of HIV infection among high-risk groups in Iran: a systematic review and meta-analysis
1
Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2
Zahedan University of Medical Sciences, Zahedan, Iran
3
Kurdistan University of Medical Sciences, Sanandaj, Iran
4
Arak University of Medical Sciences, Arak, Iran
5
Zanjan University of Medical Sciences, Zanjan, Iran
6
Hamadan University of Medical Sciences, Hamadan, Iran
Submission date: 2020-01-21
Final revision date: 2020-09-01
Acceptance date: 2020-09-01
Publication date: 2021-04-12
HIV & AIDS Review 2021;20(1):1-9
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In Iran, data relating to an updated prevalence of human immunodeficiency virus (HIV) infection among high-risk groups are lacking. Therefore, this study aimed to determine the prevalence of HIV infection among high-risk groups in Iran through meta-analyses.
Material and methods:
Electronic scientific databases, including PubMed, SCOPUS, and Web of Knowledge were explored to identify relevant studies. Random effect model was used to estimate the pooled prevalence.
Results:
A total of 1,113 records were identified in initial search, out of which 43 reports were finally included in the study. The estimated overall prevalence among high-risk groups was 0.06%, which ranged from 0 among drug addict prisoners in the North to 0.2 among drug addicts in the South of Iran.
Conclusions:
Prevalence of HIV among high-risk groups in Iran is relatively low. The prevalence of HIV in high-risk groups in different parts of Iran has a different pattern. Due to significant prevalence of HIV in injecting drug users compared to other high-risk groups, there is a need to pay serious attention to this high-risk group and adopt preventive strategies.
In Iran, data relating to an updated prevalence of human immunodeficiency virus (HIV) infection among high-risk groups are lacking. Therefore, this study aimed to determine the prevalence of HIV infection among high-risk groups in Iran through meta-analyses.
Material and methods:
Electronic scientific databases, including PubMed, SCOPUS, and Web of Knowledge were explored to identify relevant studies. Random effect model was used to estimate the pooled prevalence.
Results:
A total of 1,113 records were identified in initial search, out of which 43 reports were finally included in the study. The estimated overall prevalence among high-risk groups was 0.06%, which ranged from 0 among drug addict prisoners in the North to 0.2 among drug addicts in the South of Iran.
Conclusions:
Prevalence of HIV among high-risk groups in Iran is relatively low. The prevalence of HIV in high-risk groups in different parts of Iran has a different pattern. Due to significant prevalence of HIV in injecting drug users compared to other high-risk groups, there is a need to pay serious attention to this high-risk group and adopt preventive strategies.
REFERENCES (65)
1.
Zack MM, Moriarty DG, Stroup DF, Ford ES, Mokdad AH. Worsening trends in adult health-related quality of life and self-rated health – United States, 1993-2001. Public Health Rep 2004; 119: 493.
4.
WHO. HIV/AIDS Fact sheet; 2016. Available at: http://www.who.int/mediacentre... (Accessed: 19.11.2016).
5.
Solomon SS, Srikrishnan AK, Mehta SH, et al. High prevalence of HIV, HIV/hepatitis C virus co-infection and risk behaviors among IDUs in Chennai, India: a cause for concern. J Acquir Immune Def Syndr (1999) 2008; 49: 327.
6.
Inciardi JA, Surratt HL, Kurtz SP. HIV, HBV, and HCV infections among drug-involved, inner-city, street sex workers in Miami, Florida. AIDS Behav 2006; 10: 139-147.
9.
Zamani S, Kihara M, Gouya MM, et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Def Syndr 2006; 42: 342-346.
10.
Kazerooni PA, Motazedian N, Motamedifar M, et al. The prevalence of human immunodeficiency virus and sexually transmitted infections among female sex workers in Shiraz, South of Iran: by respondent-driven sampling. Int J STD AIDS 2014; 25: 155-161.
11.
Ziaee M, Sharifzadeh G, Namaee MH, Fereidouni M. Prevalence of HIV and hepatitis B, C, D infections and their associated risk factors among prisoners in Southern Khorasan Province, Iran. Iranian J Public Health 2014; 43: 229-234.
12.
Haghdoost AA, Mostafavi E, Mirzazadeh A, et al. Modelling of HIV/AIDS in Iran up to 2014. J AIDS HIV Res 2011; 3: 231-239.
13.
WHO. Hepatitis B Fact sheet; 2016. Available at: http://www.who.int/mediacentre... (Accessed: 19.11.2016).
14.
Ministry of Health and Medical Education. National guideline for HIV/AIDS control and treatment. Tehran: MOHME; 2011.
15.
WHO. Hepatitis C Fact sheet; 2016. Available at: http://www.who.int/mediacentre... (Accessed: 19.11.2016).
17.
virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Arch Iranian Med 2003; 6: 1-4.
18.
Mirahmaizadeh AR, Kadivar MR, Ghane Shirazi R, Fararooei M. Prevalence of HIV infection among intravenous drug addicts in Shiraz, 1998. Journal of Gorgan University of Medical Sciences 2001; 3: 39-42.
19.
Rahbar AR, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-.
20.
incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy 2004; 15: 151-155.
21.
Alizadeh AHM, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan-Iran. World J Gastroenterol 2005; 11: 4085.
22.
Talaie H, Shadnia S, Okazi A, Pajouhmand A, Hasanian H, Arianpoor H. The prevalence of hepatitis B, hepatitis C and HIV infections in non-IV drug opioid poisoned patients in Tehran-Iran. Pakistan J Biol Sci 2007; 10: 220-224.
23.
Soudbakhsh A, Nami M, Hadjiabdolbaghi M, Kazemi B. Transfusion transmitted virus prevalence rate in injection drug users (IDUs): a cross sectional study. Tehran University Medical Journal 2008; 66: 113-117 [In Persian].
24.
Meshkati M, Taeri K, Etedali E, Farid F. Prevalence of hepatitis B, C and HIV/AIDS in injecting drug users referred to the Behavioral Diseases Counseling Center in 2004. The first National Congress of infection in drug addicts in Iran; 2007.
26.
badi AR, Naghshvarian M. Surveying the prevalence of acquired viral infection and high-risk behaviors associated with AIDS among injecting drug users in Shiraz. Journal of Fundamentals of Mental Health 2009; 3: 175-184 [In Persian].
27.
Tajbakhsh E, Yaghubi R. Serologic evaluation of HIV contamination in Shahrekord prisoners through ELISA and Western blot. Sci J Iran Blood Transfus Organ 2008; 4: 365-368.
28.
Pourahmad M, Javady A, Karimi I, Ataei B, Kassaeian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infect Dis Clin Pract 2007; 15: 368-372.
29.
Behnaz K, Abdollah A, Fateme F, Mohammadreza R. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Gorgan prisoners. J Med Sci 2007; 7: 252-254.
30.
Imani R, Karimi A, Rouzbahani R, Rouzbahani A. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran. East Mediterr Health J 2008; 14: 1136-1141.
31.
Sharif M, Sherif A, Sayyah M. Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian J Sex Trans Dis 2009; 30: 28-30.
32.
Mirahmadizadeh AR, Majdzadeh R, Mohammad K, Forouzanfar M. Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. Iranian Red Crescent Medical Journal 2009; 11: 325.
33.
Alavi SM, Alavi L. Seroprevalence study of HCV among hospitalized intravenous drug users in Ahvaz, Iran (2001-2006). J Infect Public Health 2009; 2: 47-51.
34.
Mirzendehdel S, Nadji SA, Tabarsi P, et al. Prevalence of HPV and HIV among female drug addicts attending a drop-in center in Tehran, Iran. Int J Gynecol Obstet 2010; 108: 254-255.
35.
Lemckert AA, Goudsmit J, Barouch DH. Challenges in the search for an HIV vaccine. Eur J Epidemiol 2004; 19: 513-516.
36.
Zamani S, Radfar R, Nematollahi P, et al. Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy 2010; 21: 493-500.
37.
Kheirandish P, SeyedAlinaghi S, Hosseini M, et al. Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. J Acquir Immune Defic Syndr 2010; 53: 273-275.
38.
Hosseini M, SeyedAlinaghi S, Kheirandish P, et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med 2010; 13: 318-323.
39.
Ghasemian R, Najafi N, Amirkhanloo K. The study of infections due to injection drug abuse in the injecting drug users hospitalized at Imam Khomeini Hospital in Sari and Razi Hospital in Ghaemshahr in 2007-2009. J Mazand Univ Med Sci 2011; 21: 9-15 [In Persian].
40.
Navadeh S, Mirzazadeh A, Mousavi L, Haghdoost A, Fahimfar N, Sedaghat A. HIV, HSV2 and syphilis prevalence in female sex workers in Kerman, South-East Iran; using respondent-driven sampling. Iranian J Public Health 2012; 41: 60-65.
41.
Moradi AR, Emdadi A, Soori B, Mostafavi E. Prevalence of human immunodeficiency virus infection among injection drug users released from jail. Addict Health 2012; 4: 151-155.
42.
Majidi M. Prevalence of HIV, hepatitis B and C among drug abusers admitted to ICU of Baharloo hospital in 2010. PhD Thesis of Forensic Medicine. Tehran: Tehran University of Medical Sciences; 2012.
43.
Nokhodian Z, Yaran M, Adibi P, Kassaian N, Meshkati M, Ataei B. Seroprevalence of hepatitis B markers among incarcerated intravenous drug users. J Res Med Sci 2014; 19 (Suppl 1): S13.
44.
Sofian M, Aghakhani A, Banifazl M, et al. Viral hepatitis and HIV infection among injection drug users in a central Iranian City.
46.
Khajehkazemi R, Osooli M, Sajadi L, et al. HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey. Sex Transm Infect 2013: 89 Suppl 3: iii29-32.
47.
Sajadi L, Mirzazadeh A, Navadeh S, et al. HIV prevalence and related risk behaviours among female sex workers in Iran: results of the national biobehavioural survey, 2010. Sex Transm Infect 2013; 89 (Suppl 3): iii37-iii40.
48.
Navadeh S, Mirzazadeh A, Gouya MM, Farnia M, Alasvand R, Haghdoost AA. HIV prevalence and related risk behaviours among prisoners in Iran: results of the national biobehavioural survey, 2009. Sex Transm Infect 2013; 89 (Suppl 3): iii33-iii36.
49.
Ramezani A, Amirmoezi R, Volk JE, et al. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care 2014; 26: 1122-1126.
50.
Alihoseinpoor M. Prevalence of acquired immunodeficiency virus infection among addicts in compulsory residence center of Khorramabad county. The first international and the fifth national congress of HIV/AIDS; Tehran; 2014.
51.
Salehi A, Naghshvarian M, Marzban M, Lankarani KB. Prevalence of HIV, HCV, and High-Risk Behaviors for Substance Users in Drop in Centers in Southern Iran. J Addict Med 2015; 9: 181-187.
52.
Moayedi-Nia S, Bayat Jozani Z, Esmaeeli Djavid G, et al. HIV, HCV, HBV, HSV, and syphilis prevalence among female sex workers in Tehran, Iran, by using respondent-driven sampling. AIDS Care 2016; 28: 487-490.
53.
Malekinejad M, Mohraz M, Razani N, et al. High HIV prevalence in a respondent-driven sampling survey of injection drug users in Tehran, Iran. AIDS Behav 2015; 19: 440-449.
54.
Naderi N. Epidemiology of hepatitis C in hospitalized addicts in in Loghman Hakim Hospital, 2000-2001. MD Thesis. Tehran: Shahid Beheshti University of Medical Sciences; 2003.
55.
Ghanbarzadeh N, Najafi-Semnani M. A study of HIV and other sexually transmited infections among female prisoners in Birjand. Scientific Journal of Birjand University of Medical Sciences 2006; 13: 69-75 [In Persian].
56.
Azarkar Z, Sharifzadeh G, Miraki M. HBV, HCV and HIV prevalence among South Khorasan prisoners. Scientific Journal of Birjand University of Medical Sciences 2007; 14: 50-56 [In Persian].
58.
Prevalence of HIV, hepatitis B and C seropositivity in expired IV drug abusers in Hamedan. Forensic Medicine J 2010; 16: 253-257 [In Persian].
59.
Aminzadeh Z, Sarhangi-poor KA. Sero epidemiology of HIV, HBV, HCV and Syphilis among hospitalized IDUs in Loghman-Hakim hospital. Iranian Journal of Medical Microbiology 2007; 1: 53-56 [In Persian].
60.
Mohammadkhani-Ghiasvand A, Golian-Tehrani S, Modanlu S, Vejdani M, Babaei-Heydarabadi A, Dehghankar L. Investigation of serologic prevalence of HIV and hepatitis B infections and its relationship with behavioral risk factors among drug addicts. J Health Syst Res 2016; 12: 70-76.
61.
Shannon K, Csete J. Violence, condom negotiation, and HIV/STI risk among sex workers. JAMA 2010; 304: 573-574.
62.
Shannon K, Strathdee SA, Goldenberg SM, et al. Global epidemiology of HIV among female sex workers: influence of structural determinants. Lancet 2015; 385: 55-71.
63.
Rachlis B, Brouwer K, Mills E, Hayes M, Kerr T, Hogg R. Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend 2007; 90: 107-119.
64.
Tilson H, Aramrattana A, Bozzette S. Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence; 2007 Available at: http://www.nap.edu/openbook.ph... (Accessed: 18.02.2010).
65.
Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014-1028.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
